

## ABCs Publications

### Bacterial meningitis

2000 to present

Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, Hadler JL, Harrison LH, Farley MM, Reingold A, Bennett NM, Craig AS, Schaffner W, Thomas A, Lewis MM, Scallan E, Schuchat A for the Emerging Infections Program Network. Bacterial Meningitis in the United States, 1998-2007. *N Engl J Med* 2011; 364(21):2016-25.

1995-1999:

Schuchat A, Robinson KA, Wenger JD, Harrison LH, Farley MM, Reingold AL, Lefkowitz L, Perkins BA and the Active Surveillance Team. Bacterial meningitis in the United States in 1995. *N Engl J Med* 1997;337:970-6.

Wenger JD, Hightower AW, Facklam RR, Gaventa S, Broome CV. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. *J Infect Dis* 1990;162:1316-23.

### Group A *Streptococcus*

2000 to present

Angeles K, Nichols M, Baretta J, Baumbach J. Invasive Group A Streptococcal: New Mexico, 2004-2009. *New Mexico Epidemiology*. 2010; 2010(9).

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2010-provisional. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/surveys/gas10.pdf>.

Ahmad Y, Gertz RE, Jr., Li Z, Sakota V, Broyles LN, Van Beneden C, Facklam R, Shewmaker PL, Reingold A, Farley MM, Beall BW. Genetic relationships deduced from *emm* and multilocus sequence typing of invasive *Streptococcus dysgalactiae* subsp. *equisimilis* and *S. canis* recovered from isolates collected in the United States. *J Clin Microbiol* 2009;47 (7): 2046-54.

Broyles LN, Van Beneden C, Beall B, Facklam R, Shewmaker PL, Malpiedi P, Daily P, Reingold A, Farley MM. Population-based study of invasive disease caused by beta-hemolytic streptococci of groups other than A and B. *Clin Infect Dis* 2009;48(6):706-12.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2009. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/surveys/gas09.pdf>.

Lauth X, von Kockritz-Blickwede M, McNamara CW, Myskowski S, Zinkernagel AS, Beall B, Ghosh P, Gallo RL, and Nizet V. M1 protein allows group A Streptococcal survival in phagocyte extracellular traps through Cathelicidin inhibition. *J Innate Immun* 2009; 1:202-14.

Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR. Global *emm* type distribution of group A streptococci: systematic review and implications for vaccine development. *Lancet Infect Dis* 2009;10:611-6.

Centers for Disease Control and Prevention. Group A streptococcal M protein gene database. Downloadable FTP databases; updated 12/18/08. Available via the internet:  
<http://www.cdc.gov/ncidod/biotech/strep/strepblast.html>

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2008. Available via the Internet:  
<http://www.cdc.gov/abcs/reports-findings/survreports/gas08.pdf>.

Rainbow J, Jewell B, Danilla RN, Boxrud D, Beall B, Van Beneden C, Lynfield. Invasive Group A Streptococcal Disease in Nursing Homes, Minnesota, 1995-2006. *Emerg Infect Dis* 2008;14(5):772-77.

Woodbury RL, Klammer KA, Xiong Y, Bailiff T, Glennen A, Bartkus JM, Lynfield R, Van Beneden C, and Beall BW for the ABCs Team. Plasmid-borne erm(t) from invasive, macrolide-resistant *Streptococcus pyogenes* Strains. *Antimicrob Agents Chemother* 2008;52(3):1140-3.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2007. Available via the Internet:  
<http://www.cdc.gov/abcs/reports-findings/survreports/gas07.pdf>.

O'Loughlin RE, Roberson A, Cieslak PR, Lynfield R, Gershman K, Craig A, Albanese BA, Farley MM, Barrett NL, Spina NL, Beall B, Harrison LH, Reingold A, and Van Beneden C for ABCs Team. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. *Clin Infect Dis* 2007; 45:853-61.

Thigpen MC, Richards CL, Lynfield R, Barrett NL, Harrison LH, Arnold KE, Reingold A, Bennett NM, Craig AS, Gershman K, Cieslak PR, Lewis P, Greene CM, Beall B, and Van Beneden CA for ABCs/EIP. Invasive group A streptococcal infection in older adults in long-term care facilities and the community, United States, 1998-2003. *Emerg Infect Dis* 2007;13:1852-59.

Arnold KE, Schweitzer JL, Wallace B, Salter M, Neeman R, Hlady WG, Beall B. Tightly clustered outbreak of group A streptococcal disease at a long-term care facility. *Infect Control Hosp Epidemiol* 2006;12:1377-84.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2006. Available via the Internet:  
<http://www.cdc.gov/abcs/reports-findings/survreports/gas06.pdf>

Johnson DR, Kaplan EL, VanGheem A, Facklam RR, Beall B. Characterization of group A streptococci (*Streptococcus pyogenes*): correlation of M-protein and *emm*-gene type with T-protein agglutination pattern and serum opacity factor. *J Med Microbiol.* 2006;55:157-64.

Persson J, Beall B, Linse S, Lindhal G. Extreme sequence divergence but conserved ligand-binding specificity in *Streptococcus pyogenes* M protein. *PLoS Pathog* 2006; 2(5):e47.

Pletz MW, McGee L, Van Beneden CA, Petit S, Bardsley M, Barlow M, Klugman KP. The emergence of fluoroquinolone-resistance in invasive *Streptococcus pyogenes* isolates due to spontaneous mutation and horizontal gene transfer. *Antimicrob Agents Chemother.* 2006;50:943-8.

Sakota V, Fry AM, Lietman TM, Facklam RR, Li Z, Beall B. Genetically diverse group A streptococci from children in far-western Nepal share high genetic relatedness with isolates from other countries. *J Clin Microbiol* 2006;44(6):2160-6.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2005. Available via the Internet:  
<http://www.cdc.gov/abcs/reports-findings/survreports/gas05.pdf>

Dale JB, Penfound T, Chiang EY, Long V, Shulman ST, Beall B. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. *Clin Diagn Lab Immunol*. 2005;12:833-6.

Factor SH, Levine OS, Harrison LH, Farley MM, McGeer A, Skoff T, Wright T, Schwartz B, Schuchat A. Risk factors for pediatric invasive group A streptococcal disease. *Emerg Infect Dis* 2005;11(7):1062-6.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2004. Available via the Internet:  
<http://www.cdc.gov/abcs/reports-findings/survreports/gas04.pdf>

Shulman ST, Tanz RR, Kabat K, Cederlund E, Patel D, Li Z, Sakota V, Dale JB, Beall B. Group A streptococcal pharyngitis serotype surveillance in North America, 2000-2002. *Clin Infect Dis* 2004;39:325-32.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2003. Available via the Internet:  
<http://www.cdc.gov/abcs/reports-findings/survreports/gas03.pdf>

Espinosa LE, Li Z, Rodriguez RS, Facklam R, Beall B. M-protein gene type distribution within group A streptococcal clinical isolates recovered in Mexico during years 1991-2000: Overlap with type distribution within the United States. *J. Clin Microbiol* 2003;41:373-8.

Factor SH, Levine OS, Schwartz B, Harrison LH, Farley MM, McGeer A, et al. Invasive group A streptococcal disease: risk factors for adults. *Emerg Infect Dis* 2003;9(8):970-7.

Igwe EI, Shewmaker PL, Facklam RR, Farley MM, Van Beneden C, Beall B. Identification of superantigen genes *speM*, *ssa*, and *smeZ* in invasive strains of beta-hemolytic group C and G streptococci recovered from humans. *FEMS Microbiol Lett* 2003;229(2):259-64.

Jeng A, Sakota V, Li Z, Datta V, Beall B, Nizet V. Molecular genetic analysis of a group A *Streptococcus* operon encoding serum opacity factor and a novel fibronectin-binding protein, SfbX. *J Bacteriol* 2003;185(4):1208-17.

Li Z, Sakota V, Jackson D, Franklin AR, Beall B; Active Bacterial Core Surveillance/Emerging Infections Program Network. Array of M protein gene subtypes in 1064 recent invasive group A streptococcus isolates recovered from the active bacterial core surveillance. *J Infect Dis* 2003;188(10):1587-92.

Passaro DJ, Smith DS, Hett EC, Reingold AL, Daily P, Van Beneden CA, Vugia DJ. Invasive Group A Streptococcal Infections in the San Francisco Bay Area, 1989-1999. *Epidemiol Infect* 2003;129(3): 471-8.

Robinson KA, Rothrock G, Phan Q, Sayler B, Stefonek K, Van Beneden C, Levine OS. Active Bacterial Core Surveillance/Emerging Infections Program Network. Risk for severe group A streptococcal disease among patients' household contacts. *Emerg Infect Dis* 2003;9(4):443-7.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2002. Available via the Internet:  
<http://www.cdc.gov/abcs/reports-findings/survreports/gas02.pdf>

Chuang I, Van Beneden C, Beall B, Schuchat A and the ABCs/EIP Network. Population-based surveillance for postpartum invasive group A streptococcal infections, 1995-2000. *Clin Infect Dis* 2002;35:665-70.

Espinosa LE, Li Z, Rodriguez RS, Facklam R, Beall B. M protein gene type distribution within group A streptococcal clinical isolates recovered in Mexico during years 1991-2000: Overlap with type distribution within the United States. *J Clin Microbiol* 2002;41:373-8.

Facklam RF, Martin DR, Lovgren M, Johnson DR, Efstraiou A, Thompson TA, Gowan S, Kriz P, Tyrrell GJ, Kaplan E, and Beall B. Extension of the classification for group A streptococci by addition of 22 new M protein gene sequence types from clinical isolates: *emm103* to *emm104*. *Clin Infect Dis* 2002;34:28-38.

Hu MC, Walls MA, Stroop S, Reddish M, Beall B, and Dale JB. Immunogenicity of a 26-valent group A streptococcal vaccine. *Infect Immun* 2002;70:2171-77.

O'Brien K, Beall B, Barrett NL, Cieslak, Ringold A, Farley MM, Danila, Zell ER, Facklam R, Schwartz B, Schuchat A. Epidemiology of invasive group A streptococcus disease in the United States, 1995-1999. *Clin Infect Dis* 2002;35:268-76.

The Prevention of Invasive Group A Streptococcal Infections Workshop Participants. Prevention of invasive group A streptococcal disease among household contacts of case-patients and among postpartum and post-surgical patients: Recommendations from the Centers for Disease Control and Prevention. *Clin Infect Dis* 2002;35:950-9.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2001. Available via the Internet:

[http://www.cdc.gov/abcs/reports-findings/survreports/gas01\\_provis.pdf](http://www.cdc.gov/abcs/reports-findings/survreports/gas01_provis.pdf)

Stefonek KR, Maerz LL, Nielson MP, Besser RE, Cieslak PR. Group A streptococcal puerperal sepsis preceded by positive surveillance cultures. *Obstet Gynecol* 2001;98:846-48.

Beall B, Gherardi G, Lovgren M, Forwick B, Facklam R, and Tyrrell G. *emm* and *sof* gene sequence variation in relation to serological typing of opacity factor positive group A streptococci. *Microbiol* 2000;146:1195-1209.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2000. Available via the Internet:

<http://www.cdc.gov/abcs/reports-findings/survreports/gas00.pdf>

Nizet V, Beall B, Bast DJ, Datta V, Kilburn L, Low DE, De Azavedo JC. Genetic locus for streptolysin S production by group A streptococcus. *Infect Immun* 2000;68(7):4245-54.

1995-1999:

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 1999. Available via the Internet:

<http://www.cdc.gov/abcs/reports-findings/survreports/gas99.pdf>

Facklam R, Beall B, Efstraiou A, Fischetti V, Johnson D, Kaplan E, Kriz P, Lovgren M, Martin D, Schwartz B, Totolian A, Bessen D, Hollingshead S, Rubin F, Scott J, Tyrrell, G. Demonstration of *emm* typing and validation of provisional M types for group A streptococci. *Emerg Infect Dis* 1999;5:247-53.

Hoe NP, Nakashima K, Lukomski S, Grigsby D, Liu M, Kordari P, Dou SJ, Pan X, Vuopio-Varkila J, Salmenlinna S, McGeer A, Low DE, Schwartz B, Schuchat A, Naidich S, DeLorenzo D Yun-Xin F, Musser JM. Rapid selection of structural variants of group A streptococcus complement-inhibiting protein sustains and enlarges serotype M1 epidemic waves. *Nat Med* 1999;5:924-9.

York MK, Gibbs L, Perdreau-Remington F, Brooks GF. Characterization of antimicrobial resistance in *Streptococcus pyogenes* isolates from the San Francisco Bay area of Northern California. *J Clin Microbiol* 1999;37(6):1727-31.

Beall B, Facklam R, Elliott JA, Franklin AR, Hoenes T, Jackson D, Laclaire L, Thompson T, Viswanathan R. Streptococcal *emm* types associated with T agglutination patterns and the use of conserved *emm* gene restriction fragment patterns for sub-typing group A streptococci. *J Med Microbiol* 1998;47:893-8.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 1998. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/surveys/gas98.pdf>

The Working Group on Prevention of Invasive Group A Streptococcal Infections. Prevention of invasive group A streptococcal disease among household contacts of case-patients. *JAMA* 1998;279:1206-10.

Zurawski CA, Bardsley M, Beall B, Elliott JA, Facklam RR, Schwartz B, Farley M. Invasive group A streptococcal disease in metropolitan Atlanta: a population-based assessment. *Clin Infect Dis* 1998;27:150-7.

Beall B, Facklam R, Hoenes T, Schwartz B. A survey of *emm* gene sequences from systemic *Streptococcus pyogenes* infection isolates collected in San Francisco, California; Atlanta, Georgia; and Connecticut in 1994 and 1995. *J Clin Microbiol* 1997;35:1231-5.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 1997. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/surveys/gas97.pdf>

Fiorentino TR, Beall B, Mshar P, Bessen DE. A genetic-based evaluation of principal tissue reservoir for group A streptococci isolated from normally sterile sites. *J Infect Dis* 1997;176:177-82.

Beall B, Facklam R, Thompson T. Sequencing *emm*-specific PCR products for routine and accurate typing of group A streptococci. *J Clin Microbiol* 1996;34:953-58.

## Group B *Streptococcus*

2000 to present:

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2010-provisional. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/gbs10.pdf>.

Centers for Disease Control and Prevention. Prevention of Perinatal Group B Streptococcal Disease — Revised Guidelines from CDC, 2010. Morb Mortal Wkly Rep, 2010; Vol 59:RR-10.

Centers for Disease Control and Prevention. Trends in perinatal group B streptococcal disease – United States, 2000-2006. Morb Mortal Wkly Rep 2009;58(5):109-12.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2009. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/gbs09.pdf>.

Kothari NJ, Morin CA, Glennen A, Jackson D, Harper J, Schrag SJ, Lynfield R. Invasive group B streptococcal disease in the elderly, Minnesota, USA, 2003-2007. Emerg Infect Dis 2009;15(8):1279-81.

Skoff TH, Farley MM, Petit S, Craig AS, Schaffner W, Gershman K, Harrison LH, Lynfield R, Mohle-Boetani J, Zansky S, Albanese BA, Stefonek K, Zell ER, Jackson D, Thompson T, Schrag SJ. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007. Clin Infect Dis 2009;49(1):85-92.

Van Dyke MK, Phares CR, Lynfield R, Thomas AR, Arnold KE, Craig AS, Mohle-Boetani J, Gershman K, Schaffner, Petit S, Zansky SM, Morin CA, Spina NL, Wymore K, Harrison LH, Shutt KA, Baretta J, Bulens SN, Zell ER, Schuchat A, Schrag SJ. Evaluation of Universal Antenatal Screening for Group B *Streptococcus*. New Engl J Med 2009; 360(25):2626-36.

Castor ML, Whitney CG, Como-Sabetti K, Facklam R, Ferrieri P, Bartkus J, Juni B, Cieslak P, Farley M, Dumas N, Schrag SJ, and Lynfield R. Antibiotic Resistance Patterns in Invasive Group B Streptococcal Isolates. Infect Dis Obstet Gynecol 2008:727505,2008.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2008. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/gbs08.pdf>.

Dahesh S, Hensler ME, Van Sorge NM, Gertz RE Jr, Schrag S, Nizet V, Beall BW. Point Mutation in the Group B Streptococcal pbp2x Gene Conferring Decreased Susceptibility to Beta-Lactam Antibiotics. Antimicrob Agents Chemother 2008;52(8):2915-8.

Jordan, HT, Farley, MM, Craig, A, Mohle-Boetani, J, Harrison, LH, Petit, S, Lynfield, R, Thomas, A., Zansky, S, Gershman, K., Albanese, BA, Schaffner, W., Schrag, SJ. Revisiting the Need for Vaccine Prevention of Late-Onset Neonatal Group B Streptococcal Disease: A Multi-State, Population-Based Analysis. Ped Infect Dis J 2008;27:1057-64.

Phares, CR, Lynfield, R, Farley, MM, Mohle-Boetani, J, Harrison, LH, Petit, S, Craig, AS, Schaffner, W, Zansky, SM, Gershman, K, Stefonek, KR, Albanese, BA, Zell, ER, Schuchat, A, Schrag, SJ. Epidemiology of Invasive Group B Streptococcal Disease in the United States, 1999-2005. JAMA 2008;299(17):2056-65.

Phares, CR, Schuchat, A, Schrag S.J. Invasive group B streptococcal disease in the United States. JAMA. 2008;300(14):1650.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2007. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/gbs07.pdf>

Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S, Craig AS, Schaffner W, Zansky SM, Gershman K, Stefonek KR, Albanese BA, Zell ER, Schuchat A, Schrag SJ. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2007; 299(17):2056-65.

Centers for Disease Control and Prevention. Perinatal group B streptococcal disease after universal screening recommendations --- United States, 2003-2005. Morb Mortal Wkly Rep 2007;56(28):701-5.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2006. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/gbs06.pdf>

Schrag SJ, Hadler J, Arnold KE, et al. Risk factors for invasive perinatal Escherichia coli sepsis in the era of widespread intrapartum antibiotic use. Pediatrics 2006;118(2):570-6.

Schrag SJ, Stoll BJ. Early-onset neonatal sepsis in the era of wide-spread intrapartum chemoprophylaxis. Ped Infect Dis J 2006;25(10):939-40.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2005. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/gbs05.pdf>

Centers for Disease Control and Prevention. Early-Onset and Late-Onset Neonatal Group B Streptococcal Disease – United States, 1996-2004. MMWR Morb Mortal Wkly Rep 2005;54(47):1205-8.

Eisenberg E, Craig AS, Gautam S et al. Prevention Strategies for perinatal group B streptococcal disease: beyond screening. Ped Infect Dis J 2005;24:520-4.

Law, MR , Palomaki, G , Alfirevic, Z, Gilbert, R, Heath, P, McCartney, C, Reid, T and Schrag, S. The prevention of neonatal group B streptococcal disease: a report by a working group of the Medical Screening Society. J Med Screen 2005;12:60-8.

Morin CA, White K, Schuchat A, Danila RN, Lynfield R. Perinatal group B streptococcal disease prevention, Minnesota. Emerg Infect Dis 2005;11(9):1467-9.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2004. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/gbs04.pdf>

Centers for Disease Control and Prevention. Diminishing Racial disparities in early-onset neonatal group B streptococcal disease, United States, 2000 - 2003. MMWR Morb Mortal Wkly Rep 2004; 53 (No.RR-23): 502-5.

Centers for Disease Control and Prevention. Laboratory Practices for Prenatal Group B Streptococcal Disease. MMWR Morb Mortal Wkly Rep 2004; 53 (No.RR-23): 506-9.

Balter S, Zell ER, O'Brien K, Roome A, Noga H, Thayu M, Schuchat A. Impact of intrapartum antibiotics on the care and evaluation of the newborn. *Pediatr Infect Dis* 2003;22:853-7.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2003. Available via the Internet:

<http://www.cdc.gov/abcs/reports-findings/survreports/gbs03.pdf>

Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. *Lancet Infect Dis* 2003;3(4):201-13.

Schrag SJ, Arnold KE, Mohle-Boetani JC, Lynfield R, Zell ER, Stefonek K, Noga H, Craig AS, Sanza LT, Smith G, Schuchat A. Prenatal Screening for Infectious Diseases and Opportunities for Prevention. *Obstet Gynecol* 2003;102:753-60.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2002. Available via the Internet:

<http://www.cdc.gov/abcs/reports-findings/survreports/gbs02.pdf>

Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease. *MMWR Morb Mortal Wkly Rep* 2002;51(No.RR-11):1-22.

Hyde TB, Hilger TM, Reingold A, Farley MM, O'Brien KL, and Schuchat A for the Active Bacterial Core surveillance (ABCs) of the Emerging Infections Program Network. Trends in the incidence and antimicrobial resistance of early-onset sepsis: population-based surveillance in San Francisco and Atlanta. *Pediatrics* 2002;110(4):690-5.

Schrag SJ, Zell ER, Lynfield R, Roome A, Arnold KE, Craig A, Harrison LH, Reingold A, Stefonek K, Smith G, Gamble M, Schuchat A. A population-based comparison of strategies to prevent early onset group B streptococcal disease in neonates. *New Engl J Med* 2002;347:233-9.

Schuchat A, Roome A, Zell ER, Linardos H, Zywicki S, O'Brien KL. Integrated monitoring of a new group B streptococcal disease prevention program and other perinatal infections. *Maternal Child Health J* 2002;6(2):107-14.

Baltimore RS, Huie SM, Meek JI, Schuchat A, O'Brien KL. Early-onset neonatal sepsis in the era of group B streptococcal prevention. *Pediatrics* 2001;108(5):1094-8.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2001. Available via the Internet:

<http://www.cdc.gov/abcs/reports-findings/survreports/gbs01.pdf>

Farley MM. Group B Streptococcal Infections in Nonpregnant Adults. *Clin Infect Dis* 2001;33:556-61.  
Henning KJ, Hall EL, Dwyer DM, Billmann L, Schuchat A, Johnson JA, Harrison LH. Invasive group B streptococcal disease in Maryland nursing home residents. *J Infect Dis* 2001;183:1138-42.

Schuchat A. Group B streptococcal infections: from trials and tribulations to triumph and trepidation. *Clin Infect Dis* 2001;33:751-6.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2000. Available via the Internet:

<http://www.cdc.gov/abcs/reports-findings/survreports/gbs00.pdf>



Centers for Disease Control and Prevention. Adoption of perinatal group B streptococcal disease prevention recommendations by prenatal-care providers- Connecticut and Minnesota. MMWR Morb Mortal Wkly Rep 2000; 49(11):228-32.

Centers for Disease Control and Prevention. Early-onset group B streptococcal disease, United States, 1998-1999. MMWR Morb Mortal Wkly Rep 2000;49(35):793-6.

Centers for Disease Control and Prevention. Hospital-based policies for prevention of perinatal group B streptococcal disease, United States 1999. MMWR Morb Mortal Wkly Rep 2000; 49(41):936-40.

Factor SH, Whitney CG, Zywicki SS, Schuchat A for the Active Bacterial Core Surveillance Team. Effects of hospital policies based on 1996 group B streptococcal disease consensus guidelines. Obstet Gynecol 2000;95:377-82.

Hager WD, Schuchat A, Gibbs R, Sweet R, Mead P, Larsen JW. Prevention of perinatal group B streptococcal infection: addressing current controversies. Obstet Gynecol 2000;96:141-5.

Schrag S, Whitney CG, Schuchat A. Neonatal group B streptococcal disease: How infection control teams can contribute to prevention efforts. Infect Control Hosp Epidemiol 2000:473-83.

Schrag SJ, Zywicki S, Farley M, Reingold A, Harrison L, Lefkowitz L, Hadler J, Danila R, Cieslak P, Schuchat A. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000;342:15-20.

Schuchat A, Schrag S. Group B Streptococcus: from emerging infection to prevention success story. *In*: Scheld WM, Craig WA, Hughes JM. *Emerging Infections 4*. Washington, DC: American Society for Microbiology; 2000:107-20.

1995-1999:

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 1999. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/gbs99.pdf>

Centers for Disease Control and Prevention. Laboratory practices for prenatal group B streptococcal screening and reporting. MMWR Morb Mortal Wkly Rep 1999;48(20):426-8.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 1998. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/gbs98.pdf>

Centers for Disease Control and Prevention. Adoption of hospital policies for prevention of perinatal group B streptococcal disease – United States, 1997. MMWR Morb Mortal Wkly Rep 1998;47(32):665-70.

Harrison LH, Elliot JA, Libonati JP, Billmann L, Schuchat A, Dwyer DM, and the Maryland Bacterial Invasive Disease Surveillance Group. Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. J Infect Dis 1998;177:998-1002.

Wessels MR, Kasper DL, Johnson KD, Harrison LH. Antibody responses in invasive group B streptococcal infection in adults. J Infect Dis 1998;178:569-72.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 1997. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/gbs97.pdf>

Centers for Disease Control and Prevention. Decreasing incidence of perinatal group B streptococcal disease -- United States, 1993-1995. MMWR Morb Mortal Wkly Rep 1997;46(21):473-7.

Rosenstein NE, Schuchat A, and the Neonatal Group B Streptococcal Disease Study Group. Opportunities for prevention of perinatal group B streptococcal disease: a multi-state surveillance analysis. Obstet Gynecol 1997;90:901-6.

Whitney C, Plikaytis BD, Gozansky W, Schuchat A, Neonatal group B streptococcal disease study group. Prevention practices for perinatal group B streptococcal disease: a multistate surveillance analysis. Obstet Gynecol 1997;89:28-32.

Blumberg HM, Stephens DS, Modansky M, Erwin M, Elliott J, Facklam RR, Schuchat A, Baughman W, Farley MM. Invasive group B streptococcal disease: the emergence of serotype V. J Infect Dis 1996;173:365-73.

Jackson L, Farley M, Schuchat A. Adult group B streptococcal disease. Ann Int Med 1996;125:152-3.

Schuchat A, Whitney C, Zangwill K. Prevention of perinatal group B streptococcal disease: a public health perspective. MMWR Morb Mortal Wkly Rep 1996;45 (RR-7):1-24.

Farley MM. Group B Streptococcal Infection in Older Patients: Spectrum of Disease and Management Strategies. Drugs and Aging 1995;6:293-300.

Harrison LH, Ali A, Dwyer DM, et al. Relapsing invasive group B streptococcal infection in adults. Ann Intern Med 1995;123:421-7.

Jackson L, Hilsdon R, Farley M, Harrison L, Reingold A, Wenger JD, Schuchat A. Risk factors for group B streptococcal disease in adults. Ann Intern Med 1995;123:415-20.

*1992 - 1994:*

Schuchat A, Deaver-Robinson K, Plikaytis BD, Zangwill KM, Mohle-Boetani J, Wenger JD. Multistate case-control study of maternal risk factors for neonatal group B streptococcal disease. Pediatr Infect Dis J 1994;13:623-9.

Farley MM, Harvey RC, Stull T, Smith JD, Schuchat A, Wenger JD, Stephens DS. A population-based assessment of invasive disease due to group B streptococcus in nonpregnant adults. N Engl J Med 1993;328:1807-11.

Mohle-Boetani JC, Schuchat A, Plikaytis BD, Smith JD, Broome CV. Comparison of prevention strategies for neonatal group B streptococcal infection: A population-based economic analysis. JAMA 1993;270:1442-8.

Zangwill KM, Schuchat A, Wenger JD, and the Group B Streptococcal Disease Study Group. Group B streptococcal disease in the United States: Report from a multistate active surveillance system. MMWR Morb Mortal Wkly Rep 1992; 41 [No. SS-6]:25-32.

## ***Haemophilus influenzae***

2000 to present:

Lowther SA, Shinoda N, Juni BA, Theodore MJ, Wang X, Lawahir SL, Jackson ML, Cohn A, Danila R, Lynfield R. *Haemophilus influenzae* type b infection, vaccination, and *H. influenzae* carriage in children in Minnesota, 2008–2009. *Epidemiology and Infection*, Available on CJO 2011  
doi:10.1017/S0950268811000793.

MacNeil JR, Cohn AC, Farley M, Mair R, Baumbach J, Bennett N, Gershman K, Harrison LH, Lynfield R, Petit S, Reingold A, Schaffner W, Thomas A, Coronado F, Zell ER, Mayer LW, Clark TA, Messonnier NE. Current epidemiology and trends in invasive *Haemophilus influenzae* disease -- United States, 1989-2008. *Clin Infect Dis* 2011;53:1230-6.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2010-provisional. Available via the Internet:  
<http://www.cdc.gov/abcs/reports-findings/survreports/hib10.pdf>.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2009. Available via the Internet:  
<http://www.cdc.gov/abcs/reports-findings/survreports/hib09.pdf>.

Erwin AL, Sandstedt SA, Bonthuis PJ, Geelhood JL, Nelson KL, Unrath W CT, Diggle MA, Theodore MJ, Pleatman CR, Mothershed EA, Sacchi CT, Mayer LW, Gilsdorf JR, Smith AL. Analysis of Genetic Relatedness of *Haemophilus influenzae* Isolates by Multilocus Sequence Typing. *J Bacteriol* 2008;190(4):1473-83.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2008. Available via the Internet:  
<http://www.cdc.gov/abcs/reports-findings/survreports/hib08.pdf>.

Centers for Disease Control and Prevention. Update: Continued *Haemophilus influenzae* type b vaccine shortage and surveillance for invasive *H. influenzae* disease — United States, 2007-2008. *Morb Mortal Wkly Rep* 2008;57(46):1252-5.

Satola SW, Napier B, Farley MM. Association of IS1016 with the *hia* adhesion gene and biotype V and I in invasive nontypeable *Haemophilus influenzae*. *Infect Immun* 2008;76(11):5221-7.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2007. Available via the Internet:  
<http://www.cdc.gov/abcs/reports-findings/survreports/hib07.pdf>

Satola SW, Collins JT, Napier R, Farley MM. Capsule gene analysis of invasive *Haemophilus influenzae*: accuracy of serotyping and prevalence of IS1016 among nontypeable isolates. *J Clin Microbiol* 2007;45(10):3230-8.

Triden L, Glennen A, Juni B, Lynfield R. Invasive *Haemophilus influenzae* disease and antibiotic susceptibility of invasive isolates in Minnesota, 2002-2005. *Infect Dis Clin Pract*. November 2007;15(6):373-6.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2006. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/hib06.pdf>

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2005. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/hib05.pdf>

Kapogiannis BG, Satola S, Keyserling HL, Farley MM. Invasive Infections with *H. influenzae* Serotype a Containing an IS1016-*bexA* Partial Deletion: Possible Association with Virulence. Clin Infect Dis 2005; 41:e97-103.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2004. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/hib04.pdf>

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2003. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/hib03.pdf>

LaClaire LL, Tondella MLC, Beall DS, Nobel CA, Raghunatnan PL, Rosenstein NE, Popovic T, and the ABCs Team Members. Identification of *Haemophilus influenzae* serotypes by standard slide agglutination serotyping and PCR-based capsule typing. J Clin Microbiol 2003;41:1:393-6.

Centers for Disease Control and Prevention. 2002. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2002. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/hib02.pdf>

Ohuabunwo C, Bath S, Bisgard K, Murphy T, Shutt K, Rosenstein N. Progress Toward Elimination of *Haemophilus influenzae* Type b Invasive Disease Among Infants and Children, United States, 1998--2000. MMWR Morb Mortal Wkly Rep 2002; 51(11); 234-7.

Raghunathan PL, LaClaire LL, Tondella ML, Beall DS, Noble CS, Rosenstein NE, Popovic T. Serotyping discrepancies in *Haemophilus influenzae* type b disease, United States, 1998—1999. MMWR Morb Mortal Wkly Rep 2002;51(32);706-7.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2001. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/hib01.pdf>.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2000. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/hib00.pdf>.

1995-1999:

Centers for Disease Control and Prevention. Achievements in Public Health, 1900-1999 Impact of Vaccines Universally Recommended for Children – United States, 1990-1999. MMWR Morb Mortal Wkly Rep 1999;48(12);243-8.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 1999. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/hib99.pdf>

Jafari HS, Adams WG, Robinson KA, Plikaytis BD, Wenger JD. Efficacy of *Haemophilus influenzae* type b conjugate vaccines and persistence of disease in disadvantaged populations. The *Haemophilus Influenzae* Study Group. Am J Public Health 1999;89:364-8.

Bisgard K, Kao A, Leake J, Strebel PM, Perkins BA, Wharton M. *Haemophilus influenzae* disease in the United States, 1994-1995: Near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis 1998;4:229-37.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 1998. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/hib98.pdf>.

Centers for Disease Control and Prevention. Progress Toward Elimination of *Haemophilus influenzae* Type b Disease Among Infants and Children -- United States, 1987-1997. MMWR Morb Mortal Wkly Rep 1998;47:993-8.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 1997. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/hib97.pdf>

Centers for Disease Control and Prevention. Progress Toward Elimination of *Haemophilus influenzae* type b disease among infants and children -- United States, 1987-1995. MMWR Morb Mortal Wkly Rep 1996;45(42):901-6.

Urwin G, Krohn JA, Deaver-Robinson K, Wenger JD, Farley MM, and the *H. Influenzae* study group. Invasive *Haemophilus influenzae* serotype f disease: Clinical and epidemiological characteristics in the Hib vaccine era. Clin Inf Dis 1996;22:1069-76.

Centers for Disease Control and Prevention. Progress toward elimination of *Haemophilus influenzae* Type b disease among infants and children—United States, 1993-1994. MMWR Morb Mortal Wkly Rep 1995;44(29):545-50.

1988 – 1994:

Centers for Disease Control and Prevention. Progress Toward elimination of *Haemophilus influenzae* type b disease among infants and children--United States, 1987-1993. MMWR 1994;43(8):144-8.

Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, Wenger JD. Decline of childhood *Haemophilus influenzae* Type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:221-6.

Farley MM, Stephens DS, Brachman PS Jr, Harvey RC, Smith JD, Wenger JD. Invasive *Haemophilus influenzae* Disease in Adults: Population-Based Surveillance. Ann Intern Med 1992; 116:806-12.

Farley MM, Stephens DS, Harvey RC, Sikes RK, Wenger JD, and the CDC Meningitis Surveillance Group. Incidence and Clinical Characteristics of Invasive *Haemophilus influenzae* in Adults. J Infect Dis 1992;165:S42-3.

Wenger JD, Pierce R, Deaver K, Franklin R, Bosley G, Pigott N, Broome CV. Invasive *Haemophilus influenzae* disease: A population-based evaluation of the role of capsular polysaccharide serotype. J Infect Dis 1992;165 [Suppl. 1]:S34-5.

Wenger JD, Pierce R, Deaver KA, Plikaytis BD, Facklam RR, Broome CV, and the *Haemophilus influenzae* Vaccine Efficacy Study Group. Efficacy of *Haemophilus influenzae* type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months. *Lancet* 1991;338:395-8.

Wenger JD, Harrison LH, Hightower A, Broome CV. Day care characteristics associated with *Haemophilus influenzae* disease. *Am J Public Health* 1990;80:1455-8.

Harrison LH, Broome CV, Hightower AW. *Haemophilus influenzae* type b polysaccharide vaccine: an efficacy study. *Pediatrics* 1989;84:255-61.

Harrison LH, Broome CV, Hightower AW, Hoppe CC, Makintubee S, Sitze SL, Taylor JA, Gaventa S, Wenger JD. A day care-based study of the efficacy of *Haemophilus b* polysaccharide vaccine. *JAMA* 1988;260:1413-8.

### **Methicillin-resistant *Staphylococcus aureus* (MRSA)**

*2000 to present:*

Como-Sabetti KJ, Harriman KH, Fridkin SK, Jawahir SL, Lynfield R. Risk factors for community-associated *Staphylococcus aureus* infections: Results from parallel studies including methicillin-resistant and methicillin-sensitive *S. aureus* compared to uninfected controls. *Epidemiol Infect* 2010; 1:1-11.

Kallen A, Mu Y, Bulens S, Reingold A, Petit S, Gershman K, Ray SM, Harrison LH, Lynfield R, Dumyati G, Townes JM, Schaffner W, Patel PR, Fridkin SK for the Active Bacterial Core surveillance (ABCs) MRSA Investigators of the Emerging Infections Program. Healthcare-Associated Invasive MRSA Infections, 2005-2008. *JAMA* 2010; 304(6):641-48.

Kempker RR, Farley MM, Ladson JL, Satola S, Ray SM. Association of methicillin-resistant *Staphylococcus aureus* (MRSA) USA300 genotype with mortality in MRSA Bacteremia. *Journal of Infection* 2010; 61:372-81.

Lessa FC, Mu Y, Davies J, Murray M, Lillie M, Pearson A, Fridkin S for the Emerging Infections Program/Active Bacterial Core surveillance MRSA investigators and the Health Protection Agency Team. Comparison of Incidence of Bloodstream Infection with Methicillin-Resistant *Staphylococcus aureus* between England and United States, 2006-2007. *Clin Infect Dis* 2010;51(8):925-28.

Shukla SK, Karow ME, Brady JM, Stemper ME, Kislow J, Moore N, Wroblewski K, Chyou PH, Warshauer DM, Reed KD, Lynfield R, Schwan WR. Virulence genes and genotypic associations in nasal carriage, community-associated methicillin-susceptible and methicillin-resistant USA400 *Staphylococcus aureus* isolates. *J Clin Microbiol*. October 2010;48(10):3582-92.

Limbago B, Fosheim GE, Schoonover V, Crane CE, Nadle J, Petit S, Heltzel D, Ray SM, Harrison LH, Lynfield R, Dumyati G, Townes JM, Schaffner W, Mu Y, Fridkin SK. Characterization of methicillin-resistant *Staphylococcus aureus* isolates collected in 2005 and 2006 from patients with invasive disease: a population-based analysis. *J Clin Microbiol* 2009;47(5):1344-51.

Lucero CA, Hageman J, Zell ER, Bulens S, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Schaffner W, Fridkin SK for ABCs MRSA Investigators. Evaluating the potential public health impact of a *Staphylococcus aureus* vaccine through the use of population-based surveillance for invasive methicillin-resistant *S. aureus* disease in the United States. *Vaccine* 2009;27(37):5061-68.

Buck JM, Harriman KH, Juni BA, Gall K, Boxrud DJ, Glennen A, Danila R, Lynfield R. No change in methicillin-resistant *Staphylococcus aureus* nasal colonization rates among Minnesota school children during 2 study periods. *Infect Dis Clin Pract* 2008;16(3):163-5.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant *Staphylococcus aureus*, 2008. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/mrsa08.pdf>

Tenover FC, McAllister S, Fosheim G, McDougal LK, Carey RB, Limbago B, Lonsway D, Patel JB, Kuehnert MJ, Gorwitz R. Characterization of *Staphylococcus aureus* Isolates from Nasal Cultures Collected from Individuals in the United States in 2001 to 2004. *J Clin Microbiol* 2008;46(9):2837-41.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant *Staphylococcus aureus*, 2007. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/mrsa07.pdf>

Klevens MR, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK for ABCs MRSA Investigators. Invasive Methicillin-Resistant *Staphylococcus aureus* Infections in the United States. *JAMA* 2007; 298(15):1763-71.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant *Staphylococcus aureus*, 2006. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/mrsa06.pdf>

Klevens MR, Morrison MA, Fridkin SK, Reingold A, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati R, Townes JM, Craig AS, Fosheim G, McDougal LK, Tenover FC, for ABCs/EIP. Community-associated Methicillin-resistant *Staphylococcus aureus* and Healthcare Risk Factors. *Emerg Infect Dis* 2006;12:1991-3.

Buck JM, Como-Sabeti K, Harriman KH, Danila RN, Boxrud DJ, Glennen A, Lynfield R. Community-associated Methicillin-resistant *Staphylococcus aureus*, Minnesota, 2000-2003. *Emerg Infect Dis* 2005;11(10):1532-8.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant *Staphylococcus aureus*, 2005. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/mrsa05.pdf>

Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabeti K, Jernigan JA, Harriman K, Harrison LH, Lynfield R, Farley MM for the Active Bacterial Core Surveillance Program of The Emerging Infections Program Network. Methicillin-resistant *Staphylococcus aureus* disease in three communities. *N Engl J Med* 2005;352:1436-44.

Naimi TS, LeDell KH, Como-Sabeti K, Borchardt SM, Boxrud DJ, Etienne J, Johnson SK, Vandenesch F, Fridkin S, O'Boyle C, Danila RN, Lynfield R. Comparison of community and health care-associated methicillin-resistant *Staphylococcus aureus* infection. *JAMA* 2003;290:2976-84.

Morin C, Hadler JL. Population-based incidence and characteristics of community-onset *Staphylococcus aureus* infections with bacteremia in four metropolitan areas in Connecticut, 1998. *J Infect Dis* 2001;184:1029-34.

***Neisseria meningitidis***

2000 to present:

Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. *Morb Mortal Wkly Rep* 2011;60(40):1391-2.

Centers for Disease Control and Prevention. Updated recommendations for use of meningococcal conjugate vaccines – Advisory Committee on Immunization Practices (ACIP), 2010. *Morb Mortal Wkly Rep* 2011;60(3):72-6.

MacNeil JR, Cohn AC, Zell ER, Schmink S, Miller E, Clark T, Messonnier NE for the Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners. Early Estimate of the Effectiveness of Quadrivalent Meningococcal Conjugate Vaccine. *Pediatr Infect Dis J*. 2011; 30(6):451-5.

Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil JR, Schmink S, Muzzi A, Bambini S, Rappuoli R, Pizza M, Murphy E, Hoiseh SK, Jansen KU, Anderson AS, Harrison LH, Clark TA, Messonnier NE, Mayer LW. Prevalence and Genetic Diversity of Candidate Vaccine Antigens Among Invasive *Neisseria meningitidis* Isolates in the United States. *Vaccine*. 2011;29(29-30):4739-44.

Cohn AC, MacNeil JR, Harrison LH, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, Craig AS, Farley M, Gershman K, Petit S, Lynfield R, Reingold A, Schaffner W, Shutt KA, Zell ER, Mayer LW, Clark T, Stephens D, Messonnier NE. Changes in *Neisseria meningitidis* Disease Epidemiology in the United States, 1998-2007: Implications for Prevention of Meningococcal Disease. *Clin Infect Dis* 2010; 50(2):184-91.

Harrison LH, Shutt KA, Schmink SE, Marsh JW, Harcourt BH, Wang X, Whitney AM, Stephens DS, Cohn AC, Messonnier NER, Mayer LW. Population structure and capsular switching of invasive *Neisseria meningitidis* isolates in the pre-meningococcal conjugate vaccine era, United States, 2000-2005. *J Infect Dis* 2010; 201(8):1208-24.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2009. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/mening09.pdf>.

Wu, HM, Harcourt BH, Wei S, Hatcher CP, Novak RT, Wang, X, Juni B, Boxrud D, Rainbow J, Schmink S, Mair RD, Theodore MJ, Sander M, Miller T, Kruger K, Mayer LW, Cohn A, Clark TA, Messonnier N, and Lynfield R. Emergence of ciprofloxacin-resistant *Neisseria meningitidis* in North America. *N Engl J Med* 2009;360:886-892.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2008. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/mening08.pdf>.

Centers for Disease Control and Prevention. Report from ACIP: Decision Not to Recommend Routine Vaccination of All Children Aged 2--10 Years with MCV4. *Morb Mortal Wkly Rep* 2008;57(17):462-5.

Harrison LH, Kreiner CJ, Shutt KA, O'Leary M, Messonnier NER, Stefonek KR, Lin H, Lynfield R, Barrett NL, Arnold KE, Jones TF, Montero JT. Risk factors for meningococcal disease in students in grades 9-12. *Ped Infect Dis J* 2008;27:193-199.



Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2007. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/mening07.pdf>

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2006. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/mening06.pdf>

Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Stephens DS, and The Meningococcal Working Group. *Neisseria meningitidis* group B correlates of protection and assay standardization – International Meeting Report, Emory University, Atlanta, Georgia, United States, 16-17 March 2005. *Vaccine* 2006;24:5093-107.

Harrison LH, Jolley KA, Shutt KA, Marsh JW, O'Leary M, Thomson Sanza L, Maiden MCJ. Antigenic shift and the incidence of meningococcal infection. *J Infect Dis* 2006;193(9):1266-74.

Harrison LH, Maiden MC. Reply to Tsang et al. *J Infect Dis* 2006;194:1792-3.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2005. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/mening05.pdf>

Centers for Disease Control and Prevention. Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2005; 54(RR-7):1-21.

Dull P, Abdelwahab J, Sacchi C, Becker M, Noble C, Kaiser R, Mayer L, Whitney A, Schmink S, Dolan-Livengood J, Stephens DS, Ajello G, Creton M, Popovic T, Rosenstein N. Serogroup W-135 *Neisseria meningitidis* carriage among U.S. travelers to the 2001 Hajj. *J Infect Dis* 2005;191:33-9.

Rainbow J, Cebelinski E, Bartkus J, Glennen A, Boxrud D, Lynfield R. Rifampin-resistant meningococcal disease. *Emerg Infect Dis* 2005;11(6):977-9.

Sejvar JJ, Johnson D, Popovic T, Miller JM, Downes F, Somsel P, Weyant R, Stephens DS, Perkins B, Rosenstein NA. Assessing the risk of laboratory-acquired meningococcal disease in the United States, 1996-2000. *J Clin Microbiol* 2005;24:4811-4.

Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. *Pediatrics* 2005;115(5):1220-32.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2004. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/mening04.pdf>

McEllistrem MC, Kolano JA, Pass MA, Caugant DA, Mendelsohn A, Pacheco AGF, Shutt KA, Razeq J, Harrison LH. Epidemiologic trends and genotypes causing meningococcal disease, Maryland. *Emerg Infect Dis* 2004;10:451-6.

Mothershed EA, Sacchi CT, Whitney AM, Barnett GA, Ajello GW, Schmink S, Mayer LW, Phelan M, Taylor TH, Bernhardt SA, Rosenstein NE, Popovic T. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of *Neisseria meningitidis*. *J Clin Microbiol* 2004; 42:320-8.

Raghunathan PL, Bernhardt SA, Rosenstein NE. Opportunities for control of meningococcal disease in the United States. *Ann Rev Med* 2004;55:333-53.

Zimmer S, Stephens DS. Meningococcal conjugate vaccine. *Expert Opin Pharmacother* 2004;4:855-63.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2003. Available via the Internet:  
<http://www.cdc.gov/abcs/reports-findings/survreports/mening03.pdf>

Dolan-Livengood JM, Miller YK, Kahler CM, Reeves M, Ajello G, Stephens DS. Genetic basis for nongroublable *Neisseria meningitidis*. *J Infect Dis* 2003;187:1616-28.

Shepard CW, Rosenstein NE, Fischer M, and the Active Bacterial Core Surveillance Team. Neonatal meningococcal disease in the United States, 1990-1999. *Pediatr Infect Dis J*, 2003;22:418-22.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2002. Available via the internet:  
<http://www.cdc.gov/abcs/reports-findings/survreports/mening02.pdf>

Kellerman S, McCombs K, Ray M, Farley MM, Rosenstein N, Popovic T, Blake P, Stephens DS, and the Georgia Emerging Infections Program. Genotype-specific carriage of *Neisseria meningitidis* in Georgia counties with hyper- and hyposporadic rates of meningococcal disease. *J Infect Dis* 2002;186:40-8.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2001. Available via the Internet:  
<http://www.cdc.gov/abcs/reports-findings/survreports/mening01.pdf>

Finn R, Groves C, Coe M, Pass M, Harrison LH. A cluster of serogroup C meningococcal disease associated with attendance at a party. *South Med J* 2001;94(12):1192-4.

Harrison LH, Pass MA, Mendelsohn AB, Egri M, Pass M, Rosenstein NE, Razeq J, Roche JC. Invasive meningococcal disease in adolescents and young adults. *JAMA* 2001;286:694-9.

Lingappa JR, Rosenstein N, Zell ER, Shutt KA, Schuchat A, Perkins BA and the Active Bacterial Core Surveillance (ABCs) Team. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. *Vaccine* 2001;19(31):4566-75.

Popovic T, Schmink S, Rosenstein NA, Ajello GW, Reeves MW, Plikaytis B, Hunter SB, Ribot EM, Boxrud D, Tondella ML, Kim C, Noble C, Mothershed E, Besser J, Perkins BA. Evaluation of pulsed-field gel electrophoresis in epidemiological investigations of meningococcal disease outbreaks caused by *Neisseria meningitidis* serogroup C. *J Clin Microbiol* 2001;39(1):75-85.

Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. *N Engl J Med* 2001;344:1378-88.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2000. Available via the Internet:  
<http://www.cdc.gov/abcs/reports-findings/survreports/mening00.pdf>

Rosenstein NE, Stocker SA, Popovic T, Tenover FC, Perkins BA, and the Active Bacterial Core Surveillance Team. Antimicrobial resistance of *Neisseria meningitidis* in the United States, 1997. *Clin Infect Dis* 2000;30:212-3.

Sacchi CT, Whitney AM, Popovic T, Beall DS, Reeves MW, Plikaytis BD, Rosenstein NE, Perkins BA, Tondella MLC, Mayer LW. Diversity and prevalence of PorA types in *Neisseria meningitidis* serogroup B in the United States, 1992-1998. *J Infect Dis* 2000;182:1169-76.

Tondella M, Popovic T, Rosenstein N, Lake D, Carlone G, Perkins B. Distribution of *Neisseria meningitidis* serogroup B serosubtypes and serotypes circulating in the United States. *J Clin Microbiol* 2000;38:3323-8.

1995-1999:

Centers for Disease Control and Prevention. 1999. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 1999. Available via the Internet:

<http://www.cdc.gov/abcs/reports-findings/survreports/mening99.pdf>

Diermayer M, Hedberg K, Hoesly F, Fischer M, Perkins B, Reeves M, Fleming D. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. *JAMA*. 1999;281(16):1493-7.

Harrison LH, Dwyer DM, Maples CT, Billmann L. The risk of meningococcal infection in college students. *JAMA* 1999;281:1906-10.

Rosenstein NE, Perkins BA, Stephens D, Lefkowitz L, Cartter ML, Danila R, Cieslak P, Shutt KA, Popovic T, Schuchat A, Harrison LH, Reingold AL, and the Active Bacterial Core Surveillance Team. The changing epidemiology of meningococcal disease in the United States, 1992-1996. *J Infect Dis* 1999;180:1894-1901.

Yusuf HR, Rochat RW, Baughman WS, Gargiullo PM, Perkins BA, Brantley MD, Stephens DS. Maternal cigarette smoking and invasive meningococcal disease: a cohort study among young children in metropolitan Atlanta, 1989-1996. *Am J Public Health* 1999;89:712-7.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 1998. Available via the Internet:

<http://www.cdc.gov/abcs/reports-findings/survreports/mening98.pdf>

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 1997. Available via the Internet:

<http://www.cdc.gov/abcs/reports-findings/survreports/mening97.pdf>

Centers for Disease Control and Prevention. Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep* 1997;46 (No. RR-5):1-10.

Centers for Disease Control and Prevention. Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep* 1997;46 (No. RR-5):13-21.

Fischer M, Hedberg K, Cardosi P, Plikaytis BD, Hoesly FC, Steingart KR, et al. Tobacco smoke as a risk factor for meningococcal disease. *Pediatr Infect Dis J* 1997;16:979-83.

Raymond NJ, Reeves M, Ajello G, Baughman W, Gheesling LL, Carlone GM, Wenger JD, Stephens DS. Molecular epidemiology of sporadic (endemic) serogroup C meningococcal disease. *J Infect Dis* 1997;176:1277-84.

Swartley JS, Marfin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, Wenger JD, Stephens DS. Capsule switching of *Neisseria meningitidis*. Proc Natl Acad Sci 1997; 94:271-6.

Zangwill K, Schuchat A, Riedo FX, Pinner RW, Koo DT, Reeves MW, Wenger JD. School-based clusters of meningococcal disease in the United States: descriptive epidemiology and a case-control analysis. JAMA 1997;277:389-95.

Centers for Disease Control and Prevention. Serogroup Y meningococcal disease--Illinois, Connecticut, and selected areas, United States, 1989-1996. MMWR Morb Mortal Wkly Rep 1996;45:1010-13.

Centers for Disease Control and Prevention. Serogroup B Meningococcal Disease -- Oregon 1994. MMWR Morb Mortal Wkly Rep 1995;44:121-4.

Jackson LA, Schuchat A, Gorsky RD, Wenger JD. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. Am J Public Health 1995;85:843-5.

Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States: An emerging threat. JAMA 1995;273:383-9.

Reeves MW, Perkins BA, Diermayer M, Wenger JD. Epidemic-associated *Neisseria meningitidis* detected by multilocus enzyme electrophoresis. Emerg Infect Dis 1995;1:53-4.

Stephens DS, Hajjeh RA, Baughman WS, Harvey CH, Wenger JD, Farley MM. Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann Intern Med 1995;123:937-40.

1988 - 1994:

Jackson LA, Tenover FC, Baker C, Plikaytis BD, Reeves MW, Stocker SA, Weaver RE, Wenger JD, and the Meningococcal Disease Study Group. Prevalence of *Neisseria meningitidis* relatively resistant to penicillin in the United States, 1991. J Infect Dis 1994;169: 338-41.

Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected counties, United States, 1989-1991. MMWR Morb Mortal Wkly Rep 1993;42:21-30.

Pinner RW, Gellin BG, Bibb WF, Baker CN, Weaver R, Hunter SB, Waterman SH, Mocca LF, Frasch CE, Broome CV, and the Meningococcal Disease Study Group. Meningococcal disease in the United States - 1986. J Infect Dis 1991;164:368-74.

## ***Streptococcus pneumoniae***

2000 to present:

Beall BW, Gertz RE, Hulkower RL, Whitney CG, Moore MR, Bruegeemann AB. Shifting Genetic Structure of Invasive Serotype 19A Pneumococci in the United States. *J Infect Dis*. 2011; 203(10):1360-8.

Centers for Disease Control and Prevention. Invasive Pneumococcal Disease and 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Coverage Among Children Aged  $\leq 59$  Months – Selected U.S. Regions, 2010-2011. *Morb Mortal Wkly Rep*, 2011; 60(43): 1477-81.

Costa MA, Huang SS, Moore M, Kulldorff M, Finkelstein JA. New Approaches to Estimating National Rates of Invasive Pneumococcal Disease. *Am J Epidemiol*. 2011; 174(2):234-42.

Hampton LM, Farley MM, Schaffner W, Thomas A, Reingold A, Harrison LH, Lynfield R, Bennett NM, Petit S, Gershman K, Baumbach J, Beall B, Jorgensen J, Glennen A, Zell ER, Moore M. Prevention of Antibiotic-Nonsusceptible *Streptococcus pneumoniae* with Conjugate Vaccine. *J Infect Dis* 2011 Dec 7 [*Epub ahead of print*].

Hicks LA, Chien YW, Taylor TH Jr, Haber M, Klugman KP, on behalf of the Active Bacterial Core surveillance (ABCs) Team. Outpatient antibiotic prescribing and nonsusceptible *Streptococcus pneumoniae* in the United States, 1996-2003. *Clin Infect Dis* 2011;53:631-9.

Petit S, Altier H, Marquez C, Mandour M. Invasive Pneumococcal Disease, Connecticut, 1998-2009. *Connecticut Epidemiologist*. 2011; 31(4): 9-10.

Rosen JB, Thomas AR, Lexau CA, Reingold A, Hadler JL, Harrison LH, Bennett NM, Schaffner W, Farley MM, Beall BW, Moore MR. Geographic Variation in Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccine Introduction in the United States. *Clin Infect Dis*. 2011;53(2):137-43.

Soto K, Petit S, Hadler JL. Changing disparities in invasive pneumococcal disease by socioeconomic status and race/ethnicity, 1998-2008. *Public Health Reports*. 2011 Supp 3;126:81-88.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2010-provisional. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/spneu10.pdf>.

Centers for Disease Control and Prevention. Invasive Pneumococcal Disease in Young Children Before Licensure of 13-Valent Pneumococcal Conjugate Vaccine – United States, 2007. *Morb Mortal Wkly Rep*, 2010; 59(10): 253-257.

Centers for Disease Control and Prevention. Licensure of a 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use Among Children – Advisory Committee on Immunization Practices (ACIP). *Morb Mortal Wkly Rep*, 2010; 59(9): 258-261.

Centers for Disease Control and Prevention. Prevention of Pneumococcal Disease Among Infants and Children — Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine. *Morb Mortal Wkly Rep*, 2010; 59: RR-11.

Centers for Disease Control and Prevention. Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23). *Morb Mortal Wkly Rep*, 2010; 59(34):1102-6.

Cohen AL, Harrison LH, Farley MM, Reingold AL, Hadler J, Schaffner W, Lynfield R, Thomas AR, Campsmith M, Li J, Schuchat A, Moore MR; Active Bacterial Core surveillance Team. Prevention of Invasive Pneumococcal Disease Among HIV-Infected Adults in the Era of Childhood Pneumococcal Immunization. *AIDS* 2010; 24(14):2253-62.

Gertz RE, Zhongya L, Pimenta FC, Jackson D, Carvalho MG, Beall BW. Increased penicillin-nonsusceptibility of non-vaccine serotype (other than 19A and 6A) invasive pneumococci in post 7-valent conjugate vaccine. *J Infect Dis* 2010; 201(5):770-5.

Park SY, Van Beneden CA, Pilishvili T, Martin MT, Facklam RR, Whitney CG, for the Active Bacterial Core surveillance Team. When Pneumococcal Conjugate Vaccines Do Not Work: A Case Series of Invasive Infections among Vaccinated Children in the United States. *J Pediatr* 2010; 156:478-83.

Pilishvili T, Zell ER, Farley MM, Schaffner W, Lynfield R, Nyquist AC, Vazquez M, Bennett NM, Reingold A, Thomas A, Jackson D, Schuchat A, Whitney CG. Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use. *Pediatrics* 2010;126(1):e9-e17.

Pilishvili T, Lexau C, Farley MM, Halder J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG, Moore MR. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. *J Infect Dis* 2010;201(1):32-41.

Poehling KA, Sims L, Snively BM, Halasa NB, Mitchel E, Rhodes M, Schaffner W, Craig AS, Griffin MR. Sickle cell trait, hemoglobin C trait and invasive pneumococcal disease. *Epidemiology* 2010; 21(3):340-6.

Walter ND, Taylor TH, Shay DK, Thompson WW, Brammer L, Dowell SF, et al. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. *Clin Infect Dis* 2010;50(2):175-83.

Carvalho Mda G, Pimenta FC, Gertz RE Jr, Joshi HH, Trujillo AA, Keys LE, Findley J, Moura IS, Park IH, Hollingshead SK, Pilishvili T, Whitney CG, Nahm MH, Beall BW. ABCs Team. PCR -based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. *J Clin Microbiol* 2009;47(3):554-9.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2009. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/spneu09.pdf>.

Hsu HE, Shutt KA, Moore MR, Beall B, Bennett NM, Craig AS, Farley MM, Jorgensen JH, Lexau CA, Petit S, Reingold A, Thomas A, Whitney CG, Harrison LH. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. *N Engl J Med* 2009;360(3):244-56.

McGee L, Biek D, Ge Y, Klugman M, du Plessis M, Smith AM, Beall B, Whitney CG, Klugman KP. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 2009;53(2):552-6.

Pimenta FC, Gertz RE Jr, Roundtree A, Yu J, Nahm MH, McDonald RR, Carvalho Mda G, Beall BW. Rarely occurring 19A-like cps locus from a serotype 19F pneumococcal isolate indicates continued need of serology-based quality control for PCR-based serotype determinations. *J Clin Microbiol* 2009;47(7):2353-4.

Ray GT, Pelton SI, Klugman KP, Strutton DR, Moore MR. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. *Vaccine* 2009;27(47):6483-94.

Walter ND, Taylor TH, Dowell SF, Mathis S, Moore ME. Holiday spikes in pneumococcal disease among older adults due to pediatric serotypes. *N Engl J Med* 2009;361(26):2584-85.

Adamkiewicz TV, Silk B, Howgate J, Baughman W, Strayhorn G, Sullivan K, Farley MM. Effectiveness of the seven-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. *Pediatrics* 2008;121(3):562-9.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2008. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/surveys/spneu08.pdf>.

Centers for Disease Control and Prevention. Effects of New Penicillin Susceptibility Breakpoints for *Streptococcus pneumoniae* – United States, 2006-2007. *Morb Mortal Wkly Rep*, 2008;57(50):1353-55.  
Centers for Disease Control and Prevention. Invasive Pneumococcal Disease in Children 5 Years After Conjugate Vaccine Introduction – Eight States, 1998-2005. *Morb Mortal Wkly Rep* 2008;57(6):144-148.

Centers for Disease Control and Prevention. Pneumococcal PCR-based serotyping. Updated Oct. 17, 2008. Available via internet: <http://www.cdc.gov/ncidod/biotech/strep/pcr.htm>.

Moore MR, Gertz RE, Barkocy-Gallagher GA, Schaffner W, Lexau C, Gershman K, Reingold A, Farley M, Harrison LH, Hadler JL, Bennett NM, Thomas AR, McGee L, Pilishvili T, Brueggemann AB, Whitney CG, Jorgensen JH, Beall B. Population snapshot of emergent *Streptococcus pneumoniae* Serotype 19A in the United States, 2005. *J Infect Dis* 2008;197(7):1016-27.

Park IH, Moore MR, Treanor JJ, Pelton SI, Pilishvili T, Beall B, Shelly MA, Mahon BE, Nahm MH; the Active Bacterial Core surveillance team. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. *J Infect Dis* 2008; 198(12):1818-22.

Yu J, Carvalho Mda G, Beall B, Nahm MH. A rapid pneumococcal serotyping system based on monoclonal antibodies and PCR. *J Med Microbiol* 2008;57(Pt 2):171-8.

Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in metropolitan Atlanta after introduction of a 7-valent pneumococcal conjugate vaccine. *Clin Infect Dis* 2007;44:1569-76.

Brueggemann AB, Pai R, Crook DW, Beall B. Vaccine escape recombinants after pneumococcal vaccination in the United States. *PLoS Pathog* 2007;3(11):e168.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2007. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/surveys/spneu07.pdf>

Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, Jackson D, Thomas A, Beall B, Lynfield R, Reingold A, Farley MM, Whitney CG. ABCs/EIP. Incidence of Pneumococcal Disease Due to Non-Pneumococcal Conjugate Vaccine (PCV7) Serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. *J Infect Dis* 2007;196(9):1346-54.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2006. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/surveys/spneu06.pdf>

Barzilay EJ, O'Brien KL, Kwok YS, Hoekstra RM, Zell ER, Reid R, Santosham M, Whitney CG, Feikin DR. Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination. *Vaccine* 2006;24(7):904-13.

Beall B, McEllistrem MC, Gertz RE, Wedel S, Boxrud DJ, Gonzalez AL, Medina MJ, Pai R, Thompson TA, Harrison LH, McGee L, Whitney CG, and the ABCs Team. Pre- and post-vaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. *J Clin Microbiol* 2006;44(3):999-1017.

Flannery B, Heffernan RT, Harrison LH, Ray SM, Reingold AL, Hadler J, Schaffner W, Lynfield R, Thomas AR, Li J, Campsmith M, Whitney CG, Schuchat A. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. *Ann Intern Med* 2006;144:1-9.

Greene CM, Kyaw MH, Ray SM, Schaffner W, Lynfield R, Barrett NL, Long C, Gershman K, Pilishvili, Roberson A, Zell ER, Whitney CG, Bennett NM for the Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Preventability of Invasive Pneumococcal Disease and Assessment of Current Polysaccharide Vaccine Recommendations for Adults: United States, 2001-2003. *Clin Infect Dis* 2006;43:141-50.

Kyaw MH, Greene CM, Schaffner W, Ray SM, Shapiro M, Barrett NL, Gershman K, Craig AS, Roberson A, Zell ER, Schuchat A, Bennett NM, Whitney CG; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Adults with invasive pneumococcal disease: missed opportunities for vaccination. *Am J Prev Med.* 2006;31:286-92.

Kyaw MH, Lynfield R, Schaffner W, Craig AS, Halder J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant *Streptococcus pneumoniae*. *N Eng J Med* 2006; 354(14):1455-63.

Mahon BE, Hsu K, Karumuri S, Kaplan SL, Mason EO, Pelton SI. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. *Vaccine* 2006;24:2514-20.

Pai R, Gertz RE, Beall B. Sequential Multiplex PCR approach for determining capsular serotypes of *Streptococcus pneumoniae* isolates. *J Clin Microbiol.* 2006;44(1):124-31.

Pletz M, Shergill A, McGee L, Beall B, Whitney CG, Klugman KP. Active Bacterial Core Surveillance Team. Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates on *Streptococcus pneumoniae* in the United States. *Antimicrob Agents Chemother*; 2006; 50:1561-3.

Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, Zell E, Lexau CA, Thomas AR, Harrison LH, Reingold AL, Hadler JL, Farley MM, Anderson BJ, Schaffner W. Invasive Pneumococcal Disease Among Infants Before and After Introduction of the Pneumococcal Conjugate Vaccine. *JAMA* 2006;295(14):1668-74.

Ray GT, Whitney CG, Fireman BH, Ciruryla V, Black SB. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. *Pediatr Infect Dis J.* 2006;25(6):494-501.



Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. *Lancet*. 2006;368(9546):1495-502.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2005. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/spneu05.pdf>

Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease, United States, 1998-2003. *MMWR Morb Mortal Wkly Rep* 2005;54(36): 893-7.

Feikin DR, Klugman KP, Facklam RR, Zell ER, Schuchat A, Whitney CG, ABCs/EIP. Increased prevalence of pediatric pneumococcal serotypes in elderly adults. *Clin Infect Dis* 2005;41(4):481-7.

Heffernan RT, Barrett NL, Gallagher KM, Hadler JL, Harrison LH, Reingold AL, Khoshnoon K, Holford TR, Schuchat A. Declining incidence of invasive *Streptococcus pneumoniae* infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. *J Infect Dis* 2005;191(12):2038-45.

Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, Whitney CG; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. *J Infect Dis* 2005;192(3):377-86.

Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG, for the ABCs Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. *JAMA* 2005;294(16):2043-51.

Lipsitch, M, Whitney CG, Zell E, Kaijalainen T, Dagan R, Malley R. Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease? *PLoS Med* 2005; 2(1): e15.

McEllistrem MC, Adams JM, Shutt K, Sanza LT, Facklam RR, Whitney CG, Jorgensen JH, Harrison LH. Erythromycin-nonsusceptible *Streptococcus pneumoniae* in children, 1999-2001. *Emerg Infect Dis* 2005;11(6):969-72.

Pai R, Gertz RE, Whitney CG, Beall B. Clonal association between *Streptococcus pneumoniae* serotype 23A, circulating within the United States, and an internationally dispersed clone of serotype 23F. *J Clin Microbiol* 2005;43(11):5440-4.

Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B, Active Bacterial Core Surveillance Team. Post-vaccine genetic structure of *Streptococcus pneumoniae* serotype 19A from children in the United States. *J Infect Dis* 2005;192(11):1988-95.

Pai R, Limor J, Beall B. Use of pyrosequencing to differentiate *Streptococcus pneumoniae* serotypes 6A and 6B. *J Clin Microbiol* 2005;43(9):4820-2.

Pettigrew MM, Fennie KP. Genomic subtraction followed by dot blot screening of *Streptococcus pneumoniae* clinical and carriage isolates identifies genetic differences associated with strains that cause otitis media. *Infect Immun* 2005;73:2805-11.

Pletz MW, McGee L, Beall B, Whitney CG, Klugman KP. Interspecies recombination in type II topoisomerase genes is not a major cause of fluoroquinolone resistance in invasive *Streptococcus pneumoniae* isolates in the United States. *Antimicrob Agents Chemother* 2005;49(2):779-80.

Stephens DS, Zughaiier SM, Whitney CG, Baughman WS, Barker L, Gay K, Jackson D, Orenstein WA, Arnold K, Schuchat A, Farley MM and the Georgia Emerging Infections Program. Incidence of macrolide resistance in *Streptococcus pneumoniae* after introduction of the pneumococcal conjugate vaccine: population-based assessment. *Lancet* 2005;365:855-63.

Talbot TR, Hartert TV, Mitchel E, Halasa NB, Arbogast PG, Poehling KA, Schaffner W, Craig AS, Griffin MR. Asthma is an independent risk factor for invasive pneumococcal disease. *N Engl J Med* 2005;352:2082-90.

Wolter N, Smith AM, Farrell DJ, Schaffner W, Moore M, Whitney CG, Jorgensen JH, Klugman KP. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. *Antimicrob Agents Chemother* 2005;49(8): 3554-7.

Yu J, Lin J, Benjamin WH Jr, Waites KB, Lee CH, Nahm MH. Rapid multiplex assay for serotyping pneumococci with monoclonal and polyclonal antibodies. *J Clin Microbiol* 2005;43:156-62.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2004. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/spneu04.pdf>

Centers for Disease Control and Prevention. Effect of New Susceptibility Breakpoints on Reporting of Resistance in *Streptococcus pneumoniae* --- United States, 2003. *MMWR Morb Mortal Wkly Rep* 2004;53(07):152-4.

Flannery B, Schrag S, Bennett NM, Lynfield R, Harrison LH, Reingold A, Cieslak PR, Hadler J, Farley MM, Facklam RR, Zell ER, Whitney CG. ABCs/EIP Impact of childhood vaccination on racial disparities in invasive *Streptococcus pneumoniae* infections. *JAMA* 2004;291(18):2197-203.

Jorgensen JH, Crawford SA, McElmeel ML, Whitney CG. Comparative activities of Cethromycin and Telithromycin against recent North American isolates of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 2004;48:605-7.

Jorgensen JH, Crawford SA, McElmeel ML, Whitney CG. Detection of resistance to Gatifloxacin and Moxifloxacin in *Streptococcus pneumoniae* with the VITEK 2 instrument. *J Clin Microbiol* 2004;42:5928-30.

Klugman KP. Vaccination: A Novel Approach to Reduce Antibiotic Resistance. Editorial Commentary. *Clin Infect Dis* 2004;39(5):649.

Mavroidi A, Godoy D, Aanensen DM, Robinsom DA, Hollingshead SK, Spratt BG. Evolutionary genetics of the capsular locus of serogroup 6 pneumococci. *J Bacteriol* 2004;186(24):8181-92 .

McEllistrem MC, Noller AC, Visweswaran S, Adams JM, Harrison LH. Serotype 14 variants of the France 9V<sup>3</sup> clone from Baltimore, Maryland, can be differentiated by the *cpsB* gene. *J Clin Microbiol* 2004;42:250-6.

Pletz MW, McGee L, Jorgensen J, Beall B, Facklam RR, Whitney CG, Klugman KP. Levofloxacin-Resistant Invasive *Streptococcus pneumoniae* in the United States: Evidence for Clonal Spread and the Impact of Conjugate Pneumococcal Vaccine. *Antimicrob Agents Chemother* 2004;48(9):3491-7.

Schrag, SJ, McGee, L, Whitney, CG, Beall, B., Craig, AS, Choate, ME, Jorgensen, JH, Facklam, RR, Klugman, KP and the ABCs Team. Emergence of *Streptococcus pneumoniae* with very-high-level resistance to penicillin. *Antimicrob Agents Chemother* 2004; 48:3016–23.

Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Mitchel E, Schaffner W, Craig AS, Edwards KM, Griffin MR. Reduction in High Rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after Introduction of the Pneumococcal Conjugate Vaccine. *Clin Infect Dis* 2004;39(5):641-8.

Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Mitchel E, Schaffner W, Craig AS, Edwards KH, Griffin MR. Elimination of racial differences in invasive pneumococcal disease in young children after introduction of the conjugate pneumococcal vaccine. *Pediatr Infect Dis J* 2004;23:726-31.

Adamkiewicz TV, Sarnaik S, Buchanan GR, Iyer RV, Miller ST, Pegelow CH, Rogers ZR, Vichinsky E, Elliott J, Facklam RR, O'Brien KL, Schwartz B, Van Beneden CA, Cannon MJ, Eckman JR, Keyserling H, Sullivan K, Wong W, Wang W. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. *J. Pediatr* 2003;143(4):438-44.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2003. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/spneum03.pdf>

Dowell SF, Whitney CG, Wright C, Rose CE, and Schuchat A. Seasonal Patterns of Invasive Pneumococcal Disease. *Emerg Infect Dis* 2003;9(5):573-9.

Fry AM, Facklam RR, Whitney CG, Plikaytis BD and Schuchat A. Multistate evaluation of invasive pneumococcal diseases in adults with HIV infection: serotype and antimicrobial resistance patterns in the United States. *J Infect Dis* 2003;188(5):643-52.

Gertz, RE, McEllistrem MC, Boxrud DJ, Li Z, Sakota V, Thompson TA, Facklam RR, Besser JM, Harrison LH, Whitney CG, Beall B. Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction. *J Clin Microbiol* 2003;41(9):4194-216.

King MD, Whitney CG, Parekh FM., and Farley MM. Recurrent invasive pneumococcal disease: a population-based assessment. *Clin Infect Dis* 2003;37:1029-36.

Kupronis BA, Richards JC, Whitney CG, Team ABCS: Invasive pneumococcal disease among older adults residing in long-term care facilities and in the community. *J Am Geriatr Soc* 2003;51(11):1520-25.

McCormick AW, Whitney CG, Farley MM, Lynfield R, Harrison LH, Bennett NM, Schaffner W, Reingold A, Hadler J, Cieslak P, Samore MH, Lipsitch M. geographic diversity and temporal trends of antimicrobial resistance in *Streptococcus pneumoniae* in the United States. *Nat Med* 2003;9(4):424-30.

Restrepo MI, Velez JA, Mcelmeel ML, Whitney CG, Jorgensen JH. Activity of daptomycin against recent North American isolates of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 2003;47(9):2974-7.

Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG: Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of co morbid conditions and race. *Ann Intern Med* 2003; 138(12): 960-8.

Thomas DM, Ray SM, Morton FJ, Shevlin JD, Offutt G, Whitney C, Jacobson T. Patient education strategies to improve pneumococcal vaccination rates: a randomized trial. *J Invest Med* 2003;51(3):141-8.

Van Beneden CA, Lexau C, Baughman W, Barnes B, Bennett N, Cassidy PM, et al. Aggregated antibiograms and monitoring of drug-resistant *Streptococcus pneumoniae*. *Emerg Infect Dis* 2003;9(9):1089-95.

Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A, Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. *New Engl J Med* 2003;348(18):1737-46.

Albanese BA, Roche JC, Pass M, Whitney CG, McEllistrem MC, Harrison LH. Geographic, demographic, and seasonal differences in penicillin-resistant *Streptococcus pneumoniae* in Baltimore. *Clin Infect Dis* 2002;34(1):15-21.

Beall B, McEllistrem MC, Gertz RE Jr, Boxrud DJ, Besser JM, Harrison LH, Jorgensen JH and Whitney CG, for the Active Bacterial Core Surveillance/ Emerging Infections Program Network. Emergence of a novel penicillin resistant clone of serotype 35B *Streptococcus pneumoniae* in the United States. *J Infect Dis* 2002;186:118-22.

Braum SE, Crawford SA, McEneel ML, Whitney CG, Jorgensen JH. Comparative activities of the oxazolidinone AZD2563 and linezolid against selected recent North American isolates of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 2002;46(9):3094-5.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2002. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/surveys/spneu02.pdf>

Centers for Disease Control and Prevention. Assessment of Susceptibility Testing Practices for *Streptococcus pneumoniae* – United States, February 2000. *MMWR Morb Mortal Wkly Rep* 2002;51(18):392-4.

Fry AM, Zell ER, Schuchat A, Butler JC Whitney CG. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. *Vaccine* 2002;21:303-11.

McEllistrem MC, Mendelsohn AB, Elliott JA, Whitney CG, Albanese BA, Harrison LH. Distribution of penicillin-nonsusceptible pneumococcal clones in the Baltimore metropolitan area and variables associated with drug resistance. *Clin Infect Dis* 2002;34(5):704-7.

McEllistrem MC, Mendelsohn AB, Pass MA, Elliott JA, Whitney CG, Kolano JA, Harrison LH. Recurrent invasive pneumococcal disease in individuals with human immunodeficiency virus infection. *J Infect Dis* 2002;185:1364-8.

Morita JY, Zell ER, Danila R, Farley MM, Hadler J, Harrison LH, Lefkowitz L, Reingold A, Kupronis BA, Schuchat A, Whitney CG. Association between antimicrobial resistance among pneumococcal isolates and burden of invasive pneumococcal disease in the community. *Clin Infect Dis* 2002;35:420-7.

Schrag SJ, Zell E, Schuchat A, Whitney CG. Evaluation of sentinel surveillance for drug-resistant *Streptococcus pneumoniae*. *Emerg Inf Dis* 2002;8(5):496-502.

Shelvin JD, Summers-Bean C, Thomas D, Whitney CG, Todd D, Ray SM. A symptomatic approach for increasing pneumococcal vaccination rates at an inner-city hospital. *Am J Prev Med* 2002;22(2):92-7.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2001. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/spneu01.pdf>

Centers for Disease Control and Prevention. Resistance of *Streptococcus pneumoniae* to Fluoroquinolones -- United States, 1995--1999. MMWR Morb Mortal Wkly Rep 2001;50(37):800-4.

Ehresmann KR, Ramesh A, Como-Sabetti K, Peterson DC, Whitney CG, Moore KA. Factors associated with self-reported pneumococcal immunization among adults 65 years of age or older in the Minneapolis-St. Paul metropolitan area. Prev Med 2001;32(5):409-15.

Hyde TB, Gay K, Stephens DS, Vugia DJ, Pass M, Johnson S, Barrett NL, Schaffner W, Cieslak PR, Maupin PS, Zell ER, Jorgensen JH, Facklam RR, Whitney CG. Active Bacterial Core Surveillance/Emerging Infections Program Network. Macrolide resistance among invasive *Streptococcus pneumoniae* isolates. JAMA 2001;286(15):1857-62.

Moroney JF, Fiore AE, Harrison LH, Patterson JE, Farley M, Jorgensen JH, Phelan M, Facklam RR, Cetron MS, Breiman RF, Kolczak M, Schuchat A. Clinical outcomes of invasive pneumonia caused by *Streptococcus pneumoniae* in the era of antibiotic resistance. Clin Infect Dis 2001;33:797-805.

Robinson K, Baughman W, Rothrock G, Barrett N, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B, Patterson J, Zell E, Schuchat A, Whitney C. Epidemiology of *Streptococcus pneumoniae* infections in the U.S., 1995-1998 – Opportunities for prevention in the conjugate vaccine era. JAMA 2001;285:1729-35.

Beall B, Gherardi G, Facklam R, and Hollingshead S. Pneumococcal *psp A* sequence types of prevalent multi-resistant strains in the United States and of internationally disseminated pneumococcal clones. J Clin Microbiol 2000;38:3663-9.

Breiman RF, Keller DW, Phelan M, Sniadack D, Stephens DS, Rimland D, Farley MM, Schuchat A, Reingold A. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med. 2000;160:2633-8.

Centers for Disease Control and Prevention. 2000. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2000. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/survreports/spneu00.pdf>

Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000;49(No.RR-9):1-35.

Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, McGeer A, Farley MM, Vugia DJ, Lexau C, Stefonek KR, Patterson JE, Jorgensen JH. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000;90:223-9.

Fiore AE, Moroney JF, Farley MM, Harrison LH, Patterson JE, Jorgensen M, Kolczak MS, Breiman RF, Schuchat A. Clinical outcomes of meningitis caused by *Streptococcus pneumoniae* in the era of antibiotic resistance. Clin Infect Dis 2000;30:71-7.

Gay K, Baughman W, Miller Y, Jackson D, Whitney CG, Schuchat A, Farley MM, Tenover F, Stephens DS. The emergence of *Streptococcus pneumoniae* resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J Infect Dis 2000;182(5):1417-24.

Gherardi G, Whitney CG, Facklam RR, Beall B. Major related sets of antibiotic-resistant pneumococci in the United States as determined by PFGE and *pbp1a-pbp2b-pbp2x-dhf* restriction profiles. J Infect Dis 2000;181:216-29.

Harrison LH, Dwyer DM, Billmann L, Kolczak MS, Schuchat A, and the Maryland Emerging Infections Program. Invasive pneumococcal infection in Baltimore: implications for immunization policy. Arch Intern. Med 2000;160 (1):89-94.

Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, Plouffe JF, Rakowsky A, Schuchat A, Whitney CG. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the drug-resistant *Streptococcus pneumoniae* therapeutic working group. Arch Intern Med 2000;160:1399-1408.

Jorgensen JH, Weigel LM, Swenson JM, Whitney CG, Ferraro MJ, Tenover FC. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant *Streptococcus pneumoniae*. Antimicrob Agents Chemother 2000;44:2962-8.

McEllistrem MC, Pass M, Elliott JA, Whitney CG, Harrison LH. Clonal groups of penicillin-nonsusceptible *Streptococcus pneumoniae* in Baltimore, Maryland: A population-based, molecular epidemiologic study. J Clin Microbiol 2000;38(12):4367-72.

McEllistrem MC, Stout JE, Harrison LH. Simplified protocol for pulsed-field gel electrophoresis analysis of *Streptococcus pneumoniae*. J Clin Microbiol 2000;38:351-3.

Metlay JP, Hofmann J, Cetron MS, Fine MJ, Farley MM, Whitney C, Breiman RF. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000;30:520-8.

Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, Breiman RF, and the Active Bacterial Core Surveillance Team. Cigarette smoking and invasive pneumococcal disease. N Engl J Med 2000;342:681-9.

Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 2000;132:182-90.

Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, Jorgensen JH, Schuchat A. Increasing prevalence of multidrug-resistant *Streptococcus pneumoniae* in the United States. N Engl J Med 2000;343:1917-24.

1995-1999:

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 1999. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/surveys/spneu99.pdf>

Centers for Disease Control and Prevention. Geographic variation in penicillin resistance in *Streptococcus pneumoniae*- Selected Sites, United States, 1997. MMWR Morb Mortal Wkly Rep 1999;48:656-61.

Jacobson T, Thomas D, Morton F, Offutt G, Shevlin J and Ray S. Use of a low-literacy patient education tool to enhance pneumococcal vaccination rates: a randomized controlled trial. JAMA. 1999;282:646-50.

Levine OS, Farley M, Harrison LH, Lefkowitz L, McGeer A, Schwartz B for the Active Bacterial Core Surveillance Team. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. *Pediatrics* 1999;103(3):e28.

Beall B, Facklam RR, Jackson DM, Starling HH. Rapid screening of penicillin-susceptibility in systemic pneumococcal isolates by restriction enzyme profiling of the *php 2B* gene. *J Clin Microbiol* 1998;36:2359-62.

Butler JC, Dowell SF, Breiman RF. Epidemiology of emerging pneumococcal drug resistance: implications for treatment and prevention. *Vaccine* 1998;16:1693-7.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 1998. Available via the Internet:

<http://www.cdc.gov/abcs/reports-findings/survreports/spneu98.pdf>

Chen FM, Breiman RF, Farley M, Plikaytis B, Deaver K, Cetron MS. Geocoding and linking data from population-based surveillance and the US census to evaluate the impact of median household income on the epidemiology of invasive *Streptococcus pneumoniae* infections. *Am J Epidemiol* 1998;148:1212-8.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 1997. Available via the Internet:

<http://www.cdc.gov/abcs/reports-findings/survreports/spneu97.pdf>

Centers for Disease Control and Prevention. Assessment of National Reporting of Drug-Resistant *Streptococcus pneumoniae* -- United States, 1995-1996. *MMWR Morb Mortal Wkly Rep* 1996;45:947-59.

Hofmann J, Cetron MS, Farley MM, Baughman WS, Facklam RR, Elliott JA, Deaver KA, Breiman RF. The prevalence of drug-resistant *Streptococcus pneumoniae* in Atlanta. *N Engl J Med* 1995;333:481-6.

1988-1994:

Schuchat A, Broome CV, Hightower AW, Costa S, Parkin W. Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population. *JAMA* 1991;265:3275-9.

## Other

### *2000 to present:*

Deutscher M, Lewis M, Zell ER, Taylor TH, Van Beneden C, Schrag S for the Active Bacterial Core surveillance Team. Incidence and Severity of Invasive *Streptococcus pneumoniae*, Group A *Streptococcus*, and Group B *Streptococcus* Infections Among Pregnant and Postpartum Women. *Clin Infect Dis*. 2011; 53(2):114-23.

Weston EJ, Pondo T, Lewis MM, Martell-Cleary P, Morin C, Jewell B, Daily P, Apostol M, Petit S, Farley M, Lynfield R, Reingold A, Hansen NI, Stoll BJ, Shane AJ, Zell E, Schrag SJ. The Burden of Invasive Early-onset Neonatal Sepsis in the United States, 2005-2008. *Pediatr Infect Dis J*. 2011;30(11):937-41.

Burton DC, Flannery B, Bennett NM, Farley MM, Gershman K, Harrison LH, Lynfield R, Petit S, Reingold AL, Schaffner W, Thomas A, Plikaytis BD, Rose CE, Whitney CG, Schuchat A. Socioeconomic and racial/ethnic disparities in the incidence of bacteremic pneumonia among US adults. *Am J Public Health*. 2010;100(10):1904-11.

Van Beneden C, Olsen S, Skoff T, Lynfield R. Active, population-based surveillance for infectious diseases. In: M'ikanatha NL, R; Van Beneden, CA; de Valk, H, ed. *Infectious Disease Surveillance*. 1st ed: Blackwell Publishers, pp. 32-43, 2007.

Begier EM, Barrett NL, Mshar PA, Johnson DG, Hadler JL, Connecticut Bioterrorism Field Epidemiology Response Team. Gram-positive rod surveillance for early anthrax detection. *Emerg Infect Dis*. 2005;11(9):1483-6.

Pinner RW, Rebmann CA, Schuchat A, Hughes JM. Disease surveillance and the academic, clinical, and public health communities. *Emerg Infect Dis* 2003;9(7):781-7.

Centers for Disease Control and Prevention. HIV testing among pregnant women, United States and Canada, 1998-2001. *Morb Mortal Wkly Rep* 2002;51(45):1013-6.

Hyde T, Hilger T, Reingold A, Farley MM, O'Brien, Schuchat A. Trends in incidence and antimicrobial resistance of early-onset sepsis: Population-based surveillance in San Francisco and Atlanta. *Pediatrics* 2002;110:690-5.

Schuchat A, Hilger T, Zell E, Farley MM, Reingold A, Harrison L, Lefkowitz L, Danila R, Stefonek K, Barrett N, Morse D and Pinner R, for the Active Bacterial Core Surveillance Team of the Emerging Infections Program Network. Update from the Active Bacterial Core Surveillance of the Emerging Infections Program Network. *Emerg Infect Dis* 2001;92-9.

Centers for Disease Control and Prevention. Laboratory capacity to detect antimicrobial resistance, 1998. *Morb Mortal Wkly Rep* 2000;48(51):1167-71.

### *1995-1999:*

Mead PS, Slutsker L, Dietz V, et al. Food-related Illness and Death in the United States. *Emerg Infect Dis* 1999;5(5):607-25.